BiondVax And NIH Sign Clinical Trial Agreement For A Phase 2 Tria
NESS ZIONA, Israel, November 20, 2017 /PRNewswire/ — BiondVax Pharmaceuticals Ltd. (Nasdaq: BVXV, TASE: BVXV) today announced the signing of the clinical trial agreement (CTA) for a Phase 2 clinical trial with the National Institute of Allergy and Infectious Diseases (NIAID) of the U.S. National Institutes of Health (NIH). The study is titled “A Phase II, Double-Blind, Multicenter, Randomized, Placebo-Controlled…